MCO
Molecular and Clinical Oncology
2049-9450
2049-9469
D.A. Spandidos
10.3892/mco.2021.2454
ETM-0-0-02454
Corrigendum
Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
YamaguchiYoshiyuki
KatataYousuke
SanoFuminori
TaniokaHiroaki
OkawakiMakoto
YamamuraMasahiro
NagasakaTakeshi
01
2022
25
11
2021
16
1
20
Copyright: © Yamaguchi et al.
2020
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
Mol Clin Oncol 13:Article no. 55, 2020; DOI: 10.3892/mco.2020.2125
Subsequently to the publication of this article, the authors wish to change the information that is presented in relation to the Research Ethics Committee and approval number for their prospective study, which is no longer accurated as reported. The final sentence in the ‘Study design’ subsection of the Patients and methods, as featured on p. 2 [‘This prospective study was reviewed about science and ethics and approved by the Research Ethics Committee of Kawasaki Medical School and Hospital (approval no. 240, UMIN000021797)]’ should be amended to the following: ‘This prospective study was reviewed for its science and ethics and approved by the Certified Committee for Regenerative Medicine of Kawasaki Medical School Hospital (Committee number, NB6150002; protocol number, PC6150017; Japan Registry of Clinical Trials [jRCT] number, jRCTc060190032’. Likewise, the first sentence in the ‘Ethics approval and consent to participate’ section of the Declarations on p. 7 should now read as follows: ‘The present study was reviewed and approved by the Certified Committee for Regenerative Medicine of Kawasaki Medical School Hospital (Committee number, NB6150002; protocol number, PC6150017; Japan Registry of Clinical Trials [jRCT] number, jRCTc060190032’.
The authors apologize to the readership of the Journal for any inconvenience caused.